The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

January 21, 2017

Jennifer Woyach, MD, associate professor, The Ohio State University, discusses ibrutinib resistance in patients with chronic lymphocytic leukemia.

January 04, 2017

An investigation of the tyrosine kinase inhibitor lapatinib plus whole-brain radiotherapy has entered into a phase II trial in the treatment of patients with brain metastases from HER2-positive breast cancer.

December 31, 2016

Don M. Benson Jr, MD, PhD, discusses the clinical development of KIR-targeted therapies.

August 16, 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the long-term outcomes associated with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL).

May 12, 2016

David P. Carbone, MD, PhD, shares insight on the CheckMate-032 and KEYNOTE-028 trials and others that are exploring immunotherapy in patients with small cell lung cancer.

March 01, 2016

Craig Hofmeister, MD, discusses two clinical trials examining combination regimens in relapsed/refractory patients with multiple myeloma.

December 21, 2015

John C. Byrd, MD, discusses the second-generation BTK inhibitor acalabrutinib, which had a 95% response rate in patients with relapsed/refractory chronic lymphocytic leukemia.

October 20, 2015

John C. Byrd, MD, discussed what his clinical experience has revealed about the optimal use of ibrutinib and idelalisib in chronic lymphocytic leukemia, as well as unanswered questions and challenges concerning these novel agents.

July 31, 2015

John C. Byrd, MD, discusses receiving the American Society of Hematology's 2015 William Dameshek Prize for his numerous therapeutic breakthroughs in chronic lymphocytic leukemia, his impactful career, and his goals for the future.

July 30, 2015

The utilization of idelalisib increased substantially between the first and second quarters of 2015, representing promising growth in a highly competitive setting.

July 22, 2015

Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses idelalisib (Zydelig) combinations in CLL.

July 01, 2015

Jennifer A. Woyach, MD, discusses examining the role of BTK inhibition in CLL using murine and cellular models and mechanisms of resistance to BTK inhibitor therapy.

June 29, 2015

Although the entire medical community recognizes the importance of smoking cessation- both for cancer prevention and cardiopulmonary health-supporting patients in their efforts to cease smoking is generally not done well.

June 24, 2015

OncLive spoke with Jeffrey Jones, MD, MPH, to better understand the Study 119 results, as well as the role idelalisib and other novel targeted agents will play in CLL going forward.

June 12, 2015

Richard Goldberg, MD, Ohio State University Comprehensive Cancer Center-James Cancer Hospital, discusses PD-1 blockade in tumors with mismatch repair deficiency.

September 18, 2014

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the phase III RESONATE trial.

September 09, 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising treatment landscape for patients with chronic lymphocytic leukemia.

August 25, 2014

Joseph M. Flynn, DO, MPH, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).

July 28, 2014

Joseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the impact ibrutinib has had on treating hematologic malignancies.

July 24, 2014

Tanios Bekaii-Saab, MD, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).